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Background: Prostate cancer (PCa) is characterised by great heterogeneity of the disease progression rate. Tumours range from
insignificant and not life threatening to high risk for relapse ones. Consequently, a large number of patients undergo unnecessary
treatment. miR-145 is a well-documented tumour suppressor and its expression, which is regulated by the p53 pathway, has been
found to be decreased in the majority of human malignancies. The aim of our study was to evaluate the clinical utility of miR-145
for the prognostication of PCa.
Methods: Total RNA was isolated from 137 prostate tissue specimens obtained from 73 radical prostatectomy-treated PCa
patients and 64 transurethral- or open prostatectomy-treated benign prostate hyperplasia (BPH) patients. Following
polyadenylation and reverse transcription, miR-145 levels were determined by quantitative real-time PCR assay, using SNORD48
(RNU48) for normalisation purposes.
Results: Downregulated miR-145 expression was found in PCa compared with BPH patients. The reduction of miR-145 expression
in PCa was correlated with higher Gleason score, advanced clinical stage, larger tumour diameter and higher prostate-specific
antigen (PSA) and follow-up PSA levels. In addition, higher risk for biochemical recurrence and significantly shorter disease-free
survival (DFS) was found for the PCa patients expressing lower miR-145. Focusing on ‘low- and intermediate-recurrence risk’ PCa
patients, miR-145 loss was revealed to be a reliable predictor of biochemical relapse and poor DFS independent from Gleason
score, clinical stage, PSA and patients’ age.
Conclusion: The loss of the tumour-suppressor miR-145 increases the risk for disease progression and predicts the poor survival
of PCa patients.
Prostate cancer (PCa) prevails as the most common diagnosed
malignancy in men and the third leading cause of cancer-related
deaths in developed countries (Jemal et al, 2011). This is mainly
attributed to the extension of the life expectancy and the
widespread use of prostate-specific antigen (PSA) for population
screening in the Western world.
One of the main features of PCa that physicians have to deal
with is the heterogeneity of the disease, in terms of progression rate
and whether it is life threatening. A large number of patients are
suffering from clinically insignificant tumours, which would not
have caused symptoms and death during the patient’s life. This was
further reinforced by the high rate of overdiagnosis and over-
treatment introduced by the PSA screening of the male population
(Andriole et al, 2009; Schroder et al, 2009; Diamandis, 2010).
On the other hand, a significant portion of prostate tumours are
rapidly progressive and responsible for the poor survival of the
patients irrespective of active treatment (Trapasso et al, 1994;
Zincke et al, 1994). As a consequence, the heterogeneity of prostate
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tumours is responsible for the diversity of outcomes of patients in
the same risk group (Freedland, 2011) and the emerging need of
novel biomarkers (Sardana et al, 2008).
MicroRNAs (miRNAs) are a rapidly growing family of small
(B22nt) endogenous non-coding RNA molecules able to regulate
gene expression at the post-transcriptional level (Bartel, 2004). The
mature miRNA binds usually the 30-untranslated region (30-UTR)
of the mRNAs through complete or partially complementarity,
resulting to the translational repression or/and the degradation
of the target. Taking into account that miRNAs regulate gene
expression, it becomes clear that the upstream regulation of their
own levels is crucial for cellular homeostasis and behaviour. The
deregulation of miRNA levels has been revealed as a hallmark of
the majority of human malignancies (Calin and Croce, 2006).
Consequently, the study of miRNAs is prominent in cancer-related
research nowadays, aiming to clarify their role during tumourigen-
esis and to examine their clinical efficacy (Bartels and Tsongalis,
2009; Croce, 2009).
Among the large number of studied miRNAs, hsa-miR-145-5p
(miR-145) has a well- characterised tumour-suppressor regulatory
role in the cell microenvironment (Sachdeva and Mo, 2010b).
Inhibition of cell growth, in terms of cell cycle arrest and apoptosis,
is promoted by miR-145 through the silencing of MYC (c-Myc;
Sachdeva et al, 2009), IRS-1 and -2 (Law et al, 2012), RTKN (Wang
et al, 2009), EGFR and NUDT1 (Cho et al, 2011), TNSF10 (Zaman
et al, 2010), SWAP70 (Chiyomaru et al, 2011), DFFA (DFF45;
Zhang et al, 2010), CBFB, CLINT1 and PPP3CA (Ostenfeld et al,
2010). In addition, miR-145 has been found to protect from cancer
cell invasion and metastasis throughout the repression of MUC1
(Sachdeva and Mo, 2010a), FSCN1 (Chiyomaru et al, 2010; Fuse
et al, 2011), SERPINE1 (Villadsen et al, 2012) and RPS6KB1
(p70S6K1; Xu et al, 2012). Among the predicted targets of
miR-145, SOX9 (Thomsen et al, 2010), IGF1R (Burfeind et al,
1996; Hellawell et al, 2002), ADAM17 (Karan et al, 2003) and DDC
(Avgeris et al, 2008; Wafa et al, 2012) have already been found to
have a crucial role during PCa establishment and progression, as
well as to serve the clinical management of the patients.
MIR145 maps to the 5q32 chromosomal region close to
MIR143, with which it is co-transcribed (Cordes et al, 2009). The
expression of miR-145 is controlled by p53 (Sachdeva et al, 2009;
Suzuki et al, 2009), FoxO (Gan et al, 2010), RREB1 (Kent et al,
2010) and C/EBP-b (Sachdeva et al, 2012) transcriptional factors,
as well as by the methylation status ofMIR145 promoter (Suh et al,
2011). Downregulated miR-145 levels has been documented in PCa
(Porkka et al, 2007; Ozen et al, 2008; Schaefer et al, 2010a; Larne
et al, 2012; Wach et al, 2012) and in the majority of human
malignancies studied so far.
Although the tumour-suppressor role of miR-145 is well
documented, there is no complete evaluation of its clinical utility
for PCa patients. The aim of this study was the analysis of the miR-
145 expression profile in prostate tumours, the correlation of its
levels with the clinicopathological features of the disease and the
evaluation of its prognostic significance for the patients.
MATERIALS AND METHODS
Study population. For the purpose of our study, 137 consecutive
tissue samples were obtained from 73 patients diagnosed with PCa
(Table 1) and 64 patients with benign prostate hyperplasia (BPH)
at the ‘Laiko’ General Hospital, Athens, Greece. Transurethral or
open prostatectomy was performed in BPH patients, whereas PCa
patients underwent radical retropubic prostatectomy. Following
the removal of the prostate gland from the PCa patients, a tissue
sample of approximately 200mg was sectioned from the peripheral
zone based on the preoperative features of the biopsy and on
macroscopic findings. Thereafter, the tissue sample was divided
into two mirror-image specimens, one of which was tested by a
pathologist for the presence of malignancy, whereas the remaining
one was immediately frozen in liquid nitrogen and stored at
 80 1C until the analysis. Patients who had received hormonal
therapy or radiotherapy before the surgery were not included in
our study. Our study was approved by the ethics committee of
‘Laiko General Hospital’ and performed with respect to the ethical
standards of the Declaration of Helsinki, as revised in 2008.
For the evaluation of miR-145 prognostic significance, 62 PCa
patients were successfully followed-up, whereas 11 patients were
Table 1. Correlation of miR-145 expression profile with PCa patients’
Gleason score, Clinical stage, PSA, DRE and age
No. of patients (%)
Variable
No. of
patients
miR-145-
negativea
miR-145-
positivea P-value
Gleason score
5 2 0 (0.0) 2 (100.0) 0.015b
6 22 5 (22.7) 17 (77.3)
7 (3þ4) 25 10 (40.0) 15 (60.0)
7 (4þ3) 14 9 (64.3) 5 (35.7)
8 7 5 (71.4) 2 (28.6)
9 3 3 (100.0) 0 (0.0)
Gleason score
p6 24 5 (20.8) 19 (79.2) 0.004b
7 39 19 (48.7) 20 (51.3)
X8 10 8 (80.0) 2 (20.0)
Clinical stage
pT2a 17 4 (23.5) 13 (76.5) 0.047b
pT2b 18 6 (33.3) 12 (66.7)
pT2c 10 5 (50.0) 5 (50.0)
pT3a 15 7 (46.7) 8 (53.3)
pT3b 13 10 (76.9) 3 (23.1)
Clinical stage
p pT2c 45 15 (33.3) 30 (66.7) 0.030c
X pT3a 28 17 (60.7) 11 (39.3)
PSA (ngml–1)
o4.0 7 0 (0.0) 7 (100.0) o0.001b
4.0–10.0 43 14 (32.6) 29 (67.4)
X 10.0 22 18 (81.8) 4 (18.2)
Unknown 1
DRE
Negative 27 9 (33.3) 18 (66.7) 0.145b
Positive 44 23 (52.3) 21 (47.7)
Unknown 2
Age (years)
o65 36 15 (41.7) 21 (58.3) 0.887b
65–74 32 15 (46.9) 17 (53.1)
X75 4 2 (50.0) 2 (50.0)
Unknown 1
Abbreviations: DRE¼digital rectal examination; PCa¼prostate cancer; RQ¼ relative
quantification.
aCutoff ¼ 2.97 103 RQ units, equal to the 45th percentile of the PCa patients’ cohort.
bCalculated by w2 test.
cCalculated by Fisher’s exact test.
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excluded from the monitoring plan either because of insufficient
and unclear monitoring data or because they had received adjuvant
therapy before any biochemical recurrence because of the fact that
they were considered of high risk (e.g., positive surgical margins).
National Comprehensive Cancer Network (NCCN) guidelines for
PCa were used for the stratification of PCa patients according to
their recurrence risk (Mohler et al, 2010). Biochemical relapse was
defined by two consecutive measurements of serum PSA X0.2 ng
ml–1 (Boccon-Gibod et al, 2004). Disease-free survival (DFS) was
defined as the interval between the radical prostatectomy and the
time of biochemical relapse, or the time period between the surgery
and the most recent measurement of serum PSA for the patients
who did not present biochemical recurrence. As pre-treatment PSA
was used as the last measurement prior the radical prostatectomy,
whereas follow-up PSA was used as the most recent measurement
of the non-relapsed patients or the PSA measurement at the time
of biochemical recurrence of the relapsed ones.
Extraction and polyadenylation of total RNA. Following
the pulverisation of 50–120mg of prostate tissue, total RNA was
isolated using TRI-Reagent (Molecular Research Center, Inc.,
Cincinnati, OH, USA). Polyadenylation at the 30-end of the RNAs
was performed in a 15 ml reaction containing 1 mg of total RNA,
800 mM ATP and 1U of E. coli Poly(A) Polymerase (New England
Biolabs Inc., Ipswich, MA, USA), at 37 1C for 60min (Shi and
Chiang, 2005; Mavridis et al, 2013). Total RNA concentration
and purity were determined spectrophotometrically at 260 and
280 nm, whereas RNA integrity was evaluated by agarose gel
electrophoresis.
First-strand cDNA synthesis. The polyadenylated total RNA was
thereafter used as template for the first-strand cDNA synthesis.
Reverse transcription was carried out in a 20 ml reaction using 50U
MMLV reverse transcriptase (Invitrogen, Carlsbad, CA, USA),
40U recombinant ribonuclease inhibitor (Invitrogen) and 0.25 mM
poly(T) adapter 50-GCGAGCACAGAATTAATACGACTCACTA
TAGGTTTTTTTTTTTTVN-30 (V¼G, A, C and N¼G, A, T, C)
as reaction primer, at 37 1C for 60min (Shi and Chiang, 2005;
Mavridis et al, 2013).
Quantitative real-time PCR (qPCR). A SYBR-Green fluorescent-
based qPCR assay was applied for the quantification of miR-145
levels (Shi and Chiang, 2005; Mavridis et al, 2013). Specific forward
primers for the miR-145 and the small nucleolar RNA, C/D box
48 (SNORD48), also known as RNU48, were designed according
to their published sequences (NCBI Reference Sequence:
NR_029686.1 and NR_002745.1, respectively) and in silico
specificity analysis. Specifically, the combination of the 50-CCAGT
TTTCCCAGGAATCCCTAA-30 forward primer for miR-145 or
the 50-TGATGATGACCCCAGGTAACTCT-30 forward primer for
SNORD48 with the universal reverse primer 50-GCGAGCACAG
AATTAATACGAC-30, which hybridises the above mentioned
poly(T) adapter, amplifies a 65 bp miR-145- or a 105 bp
SNORD48-specific amplicon, respectively (Supplementary
Figure 1).
The qPCR was performed in the 7500 Real-Time PCR System
using the sequence detection software (Applied Biosystems,
Carlsbad, CA, USA). The 10 ml reaction mixture consists of Kapa
SYBR Fast Universal 2X qPCR Master Mix (Kapa Biosystems Inc.,
Woburn, MA, USA), 200 nM of each PCR primer and 0.2 ng of
cDNA. The thermal protocol consists of a 3-min polymerase
activation step at 95 1C, followed by 40 cycles of denaturation
at 95 1C for 15 s and the primer annealing and extension step at
60 1C for 1min.
Melting curve analysis and agarose gel electrophoresis were
performed following the amplification in order to distinguish the
accumulation of the specific reaction products from nonspecific
ones or primer-dimers. Calibration curves for miR-145 and
SNORD48 amplification were generated by a validation experi-
ment using as template serial dilutions of a control cDNA covering
eight orders of magnitude (10–10 6 ng cDNA) (Supplementary
Figure 1). The linear increases of miR-145 (y¼  3.57xþ 13.93;
r2¼ 0.999) and SNORD48 (y¼  3.53xþ 18.88; r2¼ 0.996)
amplification indicate the 90.5% and 92.1% reaction efficiencies,
respectively, as well as the absence of PCR inhibition by the
template.
The expression analysis of miR-145 was carried out using
the 2DDCT relative quantification (RQ) method (Livak and
Schmittgen, 2001). Duplicate reactions were performed for each
tested sample and the average CT (Avg. CT) was calculated for the
quantification analysis. SNORD48 was used as an endogenous
reference control and the LNCaP PCa cell line as our assay
calibrator. More precisely, using the formula DCT¼Avg. CTmiR-145–
Avg. CT
SNORD48, the miR-145 expression of each tested sample
was normalised to the SNORD48 endogenous reference control of
the sample. Thereafter, the normalised miR-145 expression levels
of the tested samples were quantified relative to the expression
of the calibrator (RQ unitscalibrator¼ 1), using the formula
RQ unitssample¼ 2DDCT, where DDCT¼ DCTsample–DCTcalibrator.
No template controls, reverse transcriptase-negative controls,
Poly(A) polymerase-negative controls and DNA template controls
generated undetectable CT. The intra-assay %CV was calculated
to be 3.7%.
Statistical analysis. The analysis of the differences in miR-145
levels between PCa and BPH patients was performed by the
non-parametric Mann–Whitney U-test. To evaluate the ability of
miR-145 to discriminate PCa patients from BPH ones, logistic
regression and ROC analysis were used. Univariate and multi-
variate logistic regression models were used for the calculation of
the odds ratio (OR) of log10miR-145, serum PSA levels, patient’s
age and digital rectal examination (DRE). The ROC curve
was developed by plotting %sensitivity versus (100%-specificity)
and the area under curve (AUC) was calculated by the Hanley
and McNeil method.
To evaluate the miR-145 expression differences between the
different Gleason score or clinical stage groups of patients, the
non-parametric Mann–Whitney U and Kruskal–Wallis tests were
used appropriately. Using the X-tile algorithm, the 2.97 103 RQ
units of miR-145 (equal to the 45th percentile of the PCa patients’
cohort) was adopted as an optimal cutoff value to classify PCa
patients into miR-145 (þ ) and miR-145 ( ) cohorts, expressing
higher and lower miR-145 levels, respectively. The distribution of
miR-145 (þ ) and miR-145 ( ) patients to Gleason score, clinical
stage, serum PSA levels, DRE and patients’ age was analysed using
the w2 and Fisher’s exact tests. The correlation of miR-145 levels
with tumour diameter, pre-treatment PSA and follow-up PSA
levels of PCa patients was determined by the Spearman’s
correlation coefficient (rs).
The significance of miR-145 expression for the DFS of PCa
patients was assessed with Cox proportional hazards regression
analysis as well as Kaplan–Meier survival analysis using the log-
rank test. Hazard ratio (HR) was calculated for miR-145, Gleason
score, clinical stage, serum PSA levels, patient’s age and DRE, using
both univariate and multivariate regression models. Kaplan–Meier
survival curves were generated by plotting the %DFS probability
versus the time period following the radical prostatectomy.
RESULTS
miR-145 expression is downregulated in PCa patients.
Statistically significant (P¼ 0.037) underexpression of miR-145
was detected in the PCa tissues (range: 38.36–1.67 105 RQ units;
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median: 3.80 103 RQ units) compared with the BPH ones
(range: 898.57–3.37 105 RQ units; median: 6.07 103 RQ units).
ROC analysis (AUC: 0.604; 95% CI: 0.509–0.698; P¼ 0.037)
illustrated that miR-145 loss in PCa can discriminate the malignant
from the benign specimens. Moreover, the univariate logistic
regression highlighted a statistically significant (P¼ 0.020) lower
risk of suffering from PCa for the patients with high miR-145 levels
(OR: 0.484; 95% CI: 0.263–0.892). Multivariate logistic regression
models showed that the abovementioned discriminatory value of
miR-145 (OR: 0.917; 95% CI: 0.427–1.968; P¼ 0.824) is not
independent from the PSA serum concentration, patients’ age and
DRE.
The decreased miR-145 expression correlates with higher
Gleason score, late-stage tumours, larger tumour diameter and
higher PSA and follow-up PSA serum levels. The downregula-
tion of miR-145 levels in PCa patients was further associated with
higher Gleason score tumours (Figure 1A). miR-145 expression
was significantly (P¼ 0.006) reduced in the groups with
Gleason score X8 (median: 1.78 103 RQ units) and Gleason
score 7 (median: 2.95 103 RQ units) compared with the group
with Gleason score p6 (median: 9.52 103 RQ units). Analysing
miR-145 as bivariate (Table 1), 80.0% of the patients with Gleason
score X8 were characterised as miR-145 ( ) compared with the
significantly lower 48.7% and 20.8% of the patients groups with
Gleason score 7 and Gleason score p6, respectively (P¼ 0.004).
Analysis of the miR-145 levels in relation to the clinical stage of
the patients demonstrated the downregulation of miR-145
expression (P¼ 0.026) as the disease progresses to late-stage
tumours (Figure 1B). Classifying patients intoppT2c andXpT3a
cohorts, significantly lower miR-145 expression (P¼ 0.023) was
detected in the XpT3a (median: 2.26 103 RQ units) compared
with the ppT2c group (median: 6.88 103 RQ units; Figure 1C),
resulting to the characterisation as miR-145 ( ) of the 66.7% of
XpT3a patients compared with the significant lower percentage
of 33.3% of the ppT2c cohort (P¼ 0.030; Table 1).
Apart from the most significant prognostic factors of Gleason
score and clinical stage, the loss of miR-145 was found to correlate
with higher pre-treatment PSA and follow-up PSA serum levels
as well as with tumours of larger diameter (Figure 2). As pre-
treatment PSA was used as the last measurement prior the radical
prostatectomy, whereas follow-up PSA was used as the most recent
measurement of the non-relapsed patients or the PSA measure-
ment at the time of biochemical recurrence of the relapsed ones.
A statistically significant negative correlation was highlighted
between the miR-145 levels and the pre-treatment PSA of PCa
patients using Spearman’s correlation coefficient (rs:  0.403,
Po0.001; Figure 2A) or w2 test (Po0.001; Table 1). Moreover, the
reduction of miR-145 expression levels were also associated with
higher follow-up PSA (rs:  0.296, P¼ 0.020; Figure 2B) as well as
with larger tumour diameter (rs:  0.422, P¼ 0.025; Figure 2C).
The analysis of miR-145 levels with patients’ DRE and age did not
highlight any statistically significant correlation (Table 1).
The downregulation of miR-145 expression correlates with the
shorter DFS of PCa patients. Elevated risk for biochemical
recurrence was designated for the miR-145 ( ) PCa patients by
the univariate Cox proportional regression analysis (HR: 2.533;
95% CI: 1.249–5.137; P¼ 0.010), highlighting their shorter DFS
period (Table 2). Along with miR-145, the univariate analysis
indicated the unfavourable clinical value of Gleason score, clinical
stage and PSA serum levels for the outcome of PCa patients.
The prognostic significance of miR-145 for radical prostatect-
omy PCa patients was further assessed with Kaplan–Meier survival
analysis (Figure 3). Shorter DFS period was demonstrated for
miR-145 ( ) patients (average DFS: 24.52 months) compared
with miR-145 (þ ) (average DFS: 40.69 months) group (P¼ 0.007;
Figure 3A). Overall, these findings strengthen the case for an
unfavourable outcome, in terms of shorter DFS, of PCa patients
with downregulated miR-145 expression.
miR-145 loss represents an independent unfavourable
prognostic marker for the DFS of low- and intermediate-risk
PCa patients treated with radical prostatectomy. Considering
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Figure 1. Expression analysis of miR-145 related to PCa patients’
Gleason score (A) and clinical stage (B and C). The bold lanes
represent the median value (50th percentile) for each patient cohort.
P-value was calculated by ‘Kruskal–Wallis test’ (A and B) and by
‘Mann–Whitney U-test’ (C).
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the need for more accurate prediction of the low- and
intermediate-recurrence risk patients’ outcome, PCa patients were
further grouped according to their recurrence risk using NCCN
guidelines for PCa (Mohler et al, 2010).
A significantly higher risk for biochemical relapse was indicated
by the univariate Cox proportional analysis (Table 3) for the
miR-145 ( ) patients of the ‘low- and intermediate-recurrence
risk’ cohort (HR: 3.211; 95% CI: 1.071–9.622; P¼ 0.037). For the
same patients’ group, Gleason score, clinical stage, PSA serum
levels and DRE failed to have a statistically significant prognostic
value for the biochemical recurrence of the patients. This
unfavourable outcome of the miR-145 ( ) patients was revealed
to be independent from patients’ Gleason score, clinical stage, PSA
levels, age and DRE, as indicated by the multivariate models (HR:
4.467; 95% CI: 1.268–15.736; P¼ 0.020). The abovementioned
independent predictive significance of miR-145 for the ‘low- and
intermediate-recurrence risk’ patients’ outcome was further
verified and confirmed by multivariate Cox regression analysis
(Table 3) for the ‘intermediate-recurrence risk’ cohort (HR: 4.425;
95% CI: 1.112–17.613; P¼ 0.035).
The higher risk for biochemical recurrence of the miR-145 ( )
‘low- and intermediate-recurrence risk’ patients was clearly
illustrated by the Kaplan–Meier survival plots. Significantly shorter
DFS expectancy (P¼ 0.027) is attributed to the miR-145 ( )
patients (average DFS: 28.00 months) in relation to the miR-145
(þ ) ones (average DFS: 47.36 months; Figure 3B). In addition,
poor DFS of the patients expressing lower miR-145 levels was
indicated by Kaplan–Meier DFS analysis (P¼ 0.020) for the
intermediate-recurrence risk patients group (Figure 3C). Evaluat-
ing the prognostic efficacy of miR-145 for the ‘high- and very high-
recurrence risk’ PCa patients, Kaplan–Meier survival analysis
pointed out similar DFS intervals for the miR-145 ( ) and miR-
145 (þ ) patients (Figure 3D). Summarising, miR-145 proved to be
an independent unfavourable marker for the disease progression
and the DFS expectancy of the ‘low-and intermediate-recurrence
risk’ PCa patients.
DISCUSSION
PCa represents a malignancy with good response to treatment, and
therefore, guidelines and clinical practice support the active
treatment of PCa in the local or regional disease stages
(Heidenreich et al, 2011; Siegel et al, 2012). However, a significant
portion of the patients undergo treatment without any benefits.
The results from population-based PCa screening trials revealed
that the reduction of PCa-specific mortality from PSA screening
suffers from high risk of overdiagnosis, leading to treatment of
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Table 2. Cox proportional regression analysis for the prediction of the
PCa patients’ DFS
Univariate analysis Multivariate analysis
Covariant HR 95% CIa
P-
valueb HR 95% CIa
P-
valueb
miR-145
Positive 1.00 1.00
Negative 2.533 1.249–5.137 0.010 1.264 0.489–3.273 0.629
Gleason score 2.244 1.407–3.578 0.001 1.660 0.944–2.921 0.078
Clinical stage 1.504 1.178–1.922 0.001 1.151 0.818–1.621 0.419
PSA 1.092 1.035–1.151 0.001 1.034 0.957–1.117 0.397
Age 0.996 0.944–1.051 0.877 0.983 0.930–1.039 0.548
DRE 2.285 1.104–4.727 0.026 1.535 0.679–3.469 0.303
Abbreviations: CI¼ confidence interval; DFS¼disease-free survival; DRE¼digital rectal
examination; HR¼ hazard ratio; PCa¼prostate cancer.
aCI of the estimated HR.
bTest for trend.
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clinically insignificant prostate tumours (Andriole et al, 2009;
Schroder et al, 2009). Moreover, because of the heterogeneity of the
disease, a big number of patients undergo useless invasive
treatment because of the rapid progression and the immediate
relapse of the disease (Trapasso et al, 1994; Zincke et al, 1994). The
evolving role of miRNAs during tumourigenesis and cancer
progression offers a big pool of candidates for the improvement
of PCa patients’ prognosis, risk assessment and treatment decisions
(Schaefer et al, 2010b; Fendler et al, 2011).
Using the BPH patients’ cohort as control group, decreased
miR-145 expression was detected in the tissue specimens from PCa
patients. ROC analysis highlighted the ability of miR-145
expression levels to discriminate the malignant from the benign
specimens of the gland, whereas logistic regression analysis pointed
out a greater risk of suffering from PCa for patients with reduced
miR-145 levels. The loss of miR-145 expression in PCa appeared to
follow the progression of the disease to late-stage and poorly
differentiated tumours. Underexpressed miR-145 levels were
detected in high Gleason score tumours compared with well-
differentiated ones. Moreover, the patients in advanced stages were
found to express lower miR-145 levels in relation to those suffering
from early-stage tumours. Overall, these data support the tumour-
suppressor function of miR-145 for PCa cell growth and invasion
and point out the relatively higher risk of suffering from late-stage
and poorly differentiate tumours for the patients expressing lower
miR-145 levels.
Downregulated miR-145 levels have been documented in the
majority of the studied malignancies so far. miR-145 has been
proposed to be a crucial modulator of Akt and KRas pathways’
tumourigenic role in cell microenvironment. The p53 (Sachdeva
et al, 2009; Suzuki et al, 2009) and FoxO (Gan et al, 2010)
transcription factors have been found to induce miR-145
expression. Thereafter, miR-145 silences MYC (c-Myc) leading to
cell cycle arrest and apoptosis. In PCa, mutations of p53 and
hypermethylation of the MIR145 promoter region, preventing
p53 binding, were found to be responsible for the reduced miR-145
expression (Suh et al, 2011). In addition, miR-145 was found to
further enhance activation of the p53 pathway and the expression
of p53 transcriptional targets BBC3 (PUMA) and CDKN1A (P21),
highlighting the existence of a tumour-suppressor loop between
p53 and miR-145 (Spizzo et al, 2010). Focusing on KRas pathway,
the repression of miR-145, through RREB1 transcription factor,
revealed to be necessary for the KRas-mediated oncogenic cell
transformation (Kent et al, 2010).
The tumour-suppressor role of miR-145 for PCa and the
correlation of miR-145 loss with high Gleason score and late-stage
tumours, prompted us to evaluate its significance for the
prognostication of the disease. The loss of miR-145 was indeed
further associated with higher PSA serum levels prior the surgery
and during the follow-up period, as well as with larger tumour
diameter. The Cox proportional regression analysis was further
confirmed the elevated risk for biochemical recurrence for the
radical prostatectomy-treated patients with lower miR-145.
Moreover, Kaplan–Meier survival plot strongly illustrated the
significantly shorter DFS of the miR-145 ( ) patients compared
with miR-145 (þ ) ones. Overall these findings support the
unfavourable prognostic value of miR-145 loss for PCa, which was
found to correlated with higher Gleason score, advance clinical
stage, higher risk for biochemical recurrence and shorter DFS.
We thereafter hypothesised that miR-145 expression may also
serve the prognostication of the low- and intermediate-risk group
of patients. The poor outcome of the miR-145 ( ) patients was
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Figure 3. Kaplan–Meier survival curves for the DFS of PCa patients (A), low- and intermediate-recurrence risk PCa patients (B), intermediate-
recurrence risk PCa patients (C) and high- and very high-recurrence risk PCa patients (D) comparing with miR-145 expression levels. P-value
was calculated by ‘log-rank test’.
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confirmed for the ‘low- and intermediate-recurrence risk’ cohort as
well as for the ‘intermediate-recurrence risk’ group alone. The Cox
proportional regression analysis highlighted the higher risk for
biochemical relapse of the miR-145 ( ) patients. Moreover, this
unfavourable prognostic significance was revealed to be indepen-
dent from the patients’ Gleason score, clinical stage, PSA levels and
age. In addition, significantly shorter DFS was indicated for the
miR-145 ( ) patients, compared with miR-145 (þ ) patients of
the same cohorts. Focusing on ‘high- and very high-risk’ PCa
patients group, similar DFS expectancy was indicated for the
patients independently from the loss of miR-145, supporting that
the accumulation of deregulated molecular pathways in late-stage
and dedifferentiated tumours overcomes the tumour-suppressor
role of miR-145; taking this into consideration, it would be
intriguing to design a comprehensive large-scale analysis of high-
and very high-risk PCa patients. These data clearly denote the
independent and unfavourable nature of the miR-145 loss for the
outcome of the intermediate-risk of radical prostatectomy-treated
patients and support the use of miR-145 expression for the
stratification of these patients’ cohort according to their DFS
expectancy. Future studies, focusing on low-recurrence risk PCa
will further reinforce the prognostic significance of miR-145 for the
outcome prediction of low-risk group of patients and their proper
management.
Our data clearly support the tumour-suppressor role of miR-145
and highlight its clinical utility for PCa patients. The down-
regulation of miR-145 expression in PCa was further correlated
with higher Gleason score, late-stage and larger diameter tumours,
as well as higher pre-treatment and follow-up PSA serum levels.
Moreover, PCa patients expressing lower miR-145 amounts are of
significantly higher risk for disease recurrence and thus worse
survival. Finally, we have analysed the miR-145 prognostic
significance for ‘low- and intermediate-recurrence risk’
patients, where miR-145 loss was revealed to be able to designate
the PCa patients with high risk of relapse and poor survival
expectancy independently from Gleason score, clinical stage, PSA
levels and patient’s age. Overall, these findings underline the
central role of miR-145 loss for the progression of the disease and
support the potential use of miR-145 for the improvement
of patients’ prognostication, risk assessment and treatment
management.
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